Welcome to our dedicated page for Shoulder Innovations SEC filings (Ticker: SI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shoulder Innovations filings document a Delaware medical technology issuer focused on shoulder arthroplasty implants and related surgical-care technologies. Form 8-K reports cover operating results, Regulation FD disclosures, product-launch announcements, FDA-cleared indications, strategic partnership announcements, and material agreements tied to corporate facilities.
Governance filings include the definitive proxy statement for the annual meeting, director elections, board committee matters, non-employee director compensation, and stockholder voting procedures. Current reports also record director appointments, resignations, independence determinations, indemnification arrangements and other corporate-governance events.
Matthew Fraser Ahearn, Chief Operating Officer and Director of Shoulder Innovations, Inc. (SI), reported option and related common stock transactions dated 09/11/2025. The filing shows acquisitions of three option tranches exercisable into common stock: 12,286 options at a $0.9349 exercise price, 78,616 options at $2.0988, and 16,443 options at $2.4804. Following these reported transactions, the filing records beneficial ownership rising to 215,379 common shares (direct). The first option tranche is fully vested and exercisable; the third tranche vests one-fourth on April 19, 2024 and the remainder in 36 monthly increments. The form is signed by an attorney-in-fact on 09/15/2025.
Shoulder Innovations, Inc. is a commercial-stage medical device company focused on shoulder arthroplasty. The company completed a Series E preferred financing in 2025 with gross commitments of $40,130 thousand and recognized a $11,719 thousand change in fair value related to the Series E purchase option for the six months ended June 30, 2025. It completed an IPO on August 1, 2025, selling 5,000,000 shares at $15.00 and receiving approximately $64,800 thousand net proceeds. As of June 30, 2025, cash, cash equivalents and marketable securities totaled $39,635 thousand. The company had an accumulated deficit of $80,899 thousand and expects continued losses while scaling commercialization, R&D and regulatory efforts. It amended a loan facility and remains in compliance with covenants. The filing discloses litigation, product liability and regulatory risks and a 1-for-19.08 reverse stock split in July 2025.
Shoulder Innovations, Inc. filed a current report to share that it has released its financial results for the quarter ended June 30, 2025. On September 9, 2025, the company issued a press release with these results, which is furnished as Exhibit 99.1.
The company notes that the press release and related information are being furnished rather than filed, meaning they are not subject to certain liability provisions of the Exchange Act and are not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.
FMR LLC and Abigail P. Johnson report beneficial ownership of 3,848,791 shares of Shoulder Innovations Inc. common stock, representing 19.0% of the class. The filing shows FMR LLC has 3,830,491 shares with sole voting power and 3,848,791 shares with sole dispositive power; Abigail P. Johnson is reported with sole dispositive power for the same aggregate amount and no voting power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. An exhibit is referenced for a 13d-1(k) agreement and powers of attorney are referenced by prior filings.